How the semaglutide step system works — and why it matters

What does each step in the semaglutide schedule actually involve?

The licensed schedule for Wegovy moves in four upward transitions. Treatment opens at 0.25 mg weekly, a dose whose job is adjustment, not treatment. Most people feel little at this level; that is the point. After roughly four weeks, the prescriber typically moves the dose to 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the 2.4 mg maintenance dose at around week 17 of treatment. Each pen in the Wegovy range is pre-set to a specific dose, so the physical switch between steps is straightforward: a different coloured pen.

The NHS patient information for semaglutide on NHS.uk describes the schedule in plain terms and includes guidance on what to do if a dose is missed. It is worth bookmarking before you start, it takes under a minute to find and can answer a lot of the questions that come up mid-titration. Our Wegovy overview covers the broader picture if you want the context before focusing on the steps.

A higher dose does not always mean faster results. The relationship between dose and weight loss is real but not linear, and individual response varies. What the step system guarantees is a structured entry into treatment that most people tolerate well.

Why does the step titration exist, what goes wrong if you skip it?

Semaglutide slows gastric emptying and reduces appetite by acting on GLP-1 receptors in the gut and brain. Starting at full maintenance dose would expose the digestive system to that effect all at once, and for many people that produces significant nausea, vomiting, or diarrhoea. The step titration dampens that by giving the body several weeks to adapt at each level before the concentration rises again.

Jumping a step, or shortening a step below four weeks, removes that buffer. The side-effect profile of semaglutide is primarily gastrointestinal (nausea, diarrhoea, constipation, reflux) and these effects tend to peak after a dose increase before settling. Compressing the schedule means less settling time between peaks. That is uncomfortable at best and, in cases of severe vomiting, can lead to dehydration.

The clinical evidence that informs Wegovy's licence, including the STEP 1 trial published in the New England Journal of Medicine, used this same gradual escalation across thousands of participants. The results (around 15% average body-weight reduction over 68 weeks) reflect a properly titrated population. That is the benchmark, and it depends on the schedule being followed as designed.

If a step proves difficult, the right move is to discuss it with your prescriber, not to push through independently. Holding a dose for longer than four weeks is a recognised option and does not disqualify you from eventually reaching maintenance.

What happens at step 6, is there a dose above 2.4 mg?

For most of Wegovy's licensed history, 2.4 mg was the ceiling. In early 2026 that changed. The MHRA approved a 7.2 mg maintenance dose for adults with a BMI of 30 or above, initially supplied as three 2.4 mg pens per week and later, from April 2026, as a dedicated single-dose pen. Trial data reported around 20.7% average weight loss at 72 weeks, narrowing the gap with tirzepatide 15 mg results seen in the SURMOUNT-5 head-to-head study.

The titration pathway to 7.2 mg still starts at 0.25 mg; the steps below 2.4 mg do not change. The 7.2 mg level is reached only after establishing tolerance at the standard maintenance dose, under prescriber supervision. Specific dose and pen availability is confirmed at consultation, not in advance, supply of newer formats can vary. Our page on step 6 semaglutide covers the higher-dose pathway in more detail, and if you want to understand how the earlier steps feel in practice, the first step page is a good starting point.

Whether 7.2 mg is appropriate depends on individual clinical factors, tolerability, response at 2.4 mg, and the prescriber's assessment.

How does each semaglutide step compare to the whole titration timeline?

It helps to map the steps against time. At four weeks per step, the full route from 0.25 mg to 2.4 mg takes approximately 16 to 20 weeks depending on whether any step is held. That means the first four months of treatment are largely about tolerability building, not maximum effect. Many people see meaningful weight change well before reaching maintenance (the weight-loss effect compounds as the dose rises) but the prescriber's goal during this phase is a smooth, sustainable ascent rather than the quickest possible arrival at 2.4 mg.

People transferring from another provider, or resuming after a break, may not need to restart from 0.25 mg, that depends on how recently they were at a given dose and how well they tolerated it. A prescriber reviews the evidence before any decision. If you are already mid-titration and exploring how step 2 or step 3 compare, those pages walk through each level individually.

Cost across the titration is worth thinking about practically. Wegovy pricing varies by dose and provider; a full picture of what is included in treatment costs is useful before you start. At nume, every repeat order is clinically re-reviewed, there are no auto-renewals, and no step changes happen without a prescriber's sign-off. Start your free consultation to find out whether Wegovy and its titration schedule are right for you.